Cellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility
September 22 2017 - 8:40AM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a clinical-stage biopharmaceutical firm engaged in the
development of effective immunotherapies for cancer and stem cell
therapies for degenerative diseases, today announced that the Grand
Opening ceremony set for its new Shanghai facility will be held on
November 4, 2017 at 10:30am at “Pharma Valley” in Shanghai
Zhangjiang High-Tech Park. This state-of-the-art facility
will provide office and GMP space for the company’s growing needs.
“The 100,000 square-foot facility features a
top-of-the-line GMP facility with integrated
Chemistry, Manufacturing, and Controls (“CMC”) processes. We
currently have three manufacturing facilities in China (Beijing,
Shanghai, and Wuxi) with 47,300 square feet of capacity. With the
opening of the new Zhangjiang facility in Shanghai’s Pharma Valley,
we will have a total GMP capacity of 70,000 square feet,” said Tony
(Bizuo) Liu, CEO for the Company. “All plasmids and viral vectors
are produced in-house and we will have a high yield, automated,
closed cell culture system, a key differentiator in the CAR-T and
regenerative medicine space. This expansion will enable us to serve
scaled-up demand for our current and future CAR-T clinical
studies and will allow CBMG to move quickly and efficiently from
R&D into manufacturing of CAR-T cells for clinical use, IND
filings, and future commercialization.”
About Cellular Biomedicine Group Cellular
Biomedicine Group, Inc. (NASDAQ:CBMG) develops proprietary cell
therapies for the treatment of cancer and degenerative diseases. We
conduct immuno-oncology and stem cell clinical trials in China
using products from our integrated GMP laboratory. Our GMP
facilities in China, consisting of twelve independent cell
production lines, are designed and managed according to both China
and U.S. GMP standards. CBMG recently commenced two Phase I
human clinical trials in China using CAR-T to treat Refractory
Diffuse Large B-cell Lymphoma (DLBCL), a Phase I human clinical
trial to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic
Leukemia (ALL), as well as an ongoing Phase I trial in China for
AlloJoinTM (CBMG’s “Off-the-Shelf” Allogeneic Human Adipose-derived
Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis
(KOA). CBMG was recently awarded $2.29 million from the California
Institute for Regenerative Medicine (CIRM) to support pre-clinical
studies of AlloJoinTM for Knee Osteoarthritis in the United States.
The Company also recently announced a strategic partnership with GE
Healthcare Life Sciences China to establish a joint technology
laboratory to develop control processes for the manufacture of
CAR-T and stem cell therapies. To learn more about CBMG, please
visit www.cellbiomedgroup.com.
Forward-Looking Statements Statements in this
press release relating to plans, strategies, trends, specific
activities or investments, and other statements that are not
descriptions of historical facts may be forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking information is inherently subject to risks and
uncertainties, and actual results could differ materially from
those currently anticipated due to a number of factors, which
include risks inherent in doing business, trends affecting the
global economy, including the devaluation of the RMB by China in
August 2015 and other risks detailed from time to time in CBMG’s
reports filed with the Securities and Exchange Commission,
quarterly reports on form 10-Q, current reports on form 8-K and
annual reports on form 10-K. Forward-looking statements may be
identified by terms such as "may," "will," "expects," "plans,"
"intends," "estimates," "potential," or "continue," or similar
terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are
reasonable, they cannot guarantee that future results, levels of
activity, performance or achievements will be obtained. CBMG does
not have any obligation to update these forward-looking statements
other than as required by law.
Contact: Sarah Kelly Director of
Corporate Communications, CBMG +1 408-973-7884
sarah.kelly@cellbiomedgroup.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024